Navigation Links
Ontario Institute for Cancer Research Announces Enhancements to its Intellectual Property Development and Commercialization Program

TORONTO, March 8, 2011 /PRNewswire/ -- The Ontario Institute for Cancer Research (OICR) announced today it has enhanced its Intellectual Property Development and Commercialization program (IPDC), now called the IPDC Fund. The augmented program is designed to provide broader and deeper support for promising early stage technologies.

"In the face of declining private institutional investment, the new IPDC Fund is designed to offer greater support for the most promising Ontario-based anticancer technologies," said Frank Stonebanks, Vice-President, Commercialization and Chief Commercial Officer of OICR. "It will help bridge the funding gap that too often threatens the development of many early-stage projects."

"Developing intellectual property is key to creating innovative jobs in Ontario," said Glen Murray, Ontario Minister of Research and Innovation. "With the new IPDC fund, OICR is proving it's a world leader both in cancer research and in turning discoveries into viable new technologies on the market."

A common bottleneck in the commercialization of innovative technologies is the scarcity of funding in support of early stage development of inventions. The gap in funding between the traditional public granting agencies and private investors, be they corporate or venture, is often referred to as the developmental "valley of death." OICR's IPDC Fund is designed to overcome this funding gap.

Under the new IPDC Fund, a maximum of $1.5 million will be made available over three years for each eligible project. This represents a substantial increase over the previous program and adds a third year option which was previously unavailable. Additional equity investments are also possible. These enhancements provide OICR the ability to fund compelling assets and technologies and advance them from mid-late stage academic to Series "A" VC-ready investments.

In addition, any Ontario cancer-related intellectual property (IP) is now eligible for funding under the new program, an enhancement over the previous restriction to academic IP sources only.

For more information about the OICR IPDC Fund or to start the application process, please visit the Program's website at: For inquiries concerning licensing any OICR technology, please contact OICR via email at:

About OICR

OICR is an innovative cancer research and development institute dedicated to prevention, early detection, diagnosis and treatment of cancer. The Institute is an independent, not-for-profit corporation funded by the Government of Ontario through the Ministry of Research and Innovation. OICR has 500 scientific staff (located at its headquarters and in research institutes and academia across the Province of Ontario) and an $85 million annual operating budget. It has key research efforts underway in small molecules, biologics, stem cells, imaging, genomics, informatics and bio-computing, from early stage research to Phase I clinical trials.

For more information, please visit the website at

SOURCE Ontario Institute for Cancer Research (OICR)
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ontario Institute for Cancer Research Validates NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for use in Next Generation Sequencing
2. Koch Institute for Integrative Cancer Research Dedicated Today
3. Sharpest microscope tip lands Canadas Nanotech Institute in Guinness Book of World Records
4. Weizmann Institute scientists used accelerated evolution to develop enzymes that provide protection against nerve gas
5. Polaris Group and The Ludwig Institute for Cancer Research Ltd Initiate Phase 2 Trial of Amino-Acid Degrading Enzyme, ADI-PEG 20, in Patients with Small Cell Lung Cancer
6. Larta Institute NIH Success Stories Featured in 2011 California Biomedical Industry Report
7. Tufts Launches Institute for Biopharmaceutical Partnerships
8. Salk Institute Celebrates Grand Opening of the Waitt Advanced Biophotonics Center
9. Will Rogers Institute Awards Top Doctor $50,000 for Outstanding Contributions to Lung Research
10. Weizmann Institute scientists used accelerated evolution to develop enzymes that provide protection against nerve gas
11. ALS Therapy Development Institute Appoints Anil Godhwani to Board of Directors
Post Your Comments:
(Date:11/24/2015)...  Clintrax Global, Inc., a worldwide provider of clinical research services ... that the company has set a new quarterly earnings record in ... growth posted for Q3 of 2014 to Q3 of 2015.   ... , with the establishment of an Asia-Pacific ... United Kingdom and Mexico , ...
(Date:11/24/2015)... , November 24, 2015 ... market research report released by Transparency Market Research, the ... at a CAGR of 17.5% during the period between ... Market - Global Industry Analysis, Size, Volume, Share, Growth, ... non-invasive prenatal testing market to reach a valuation of ...
(Date:11/24/2015)... ... November 24, 2015 , ... InSphero AG, the leading supplier of easy-to-use solutions ... Melanie Aregger to serve as Chief Operating Officer. , Having joined InSphero ... team and was promoted to Head of InSphero Diagnostics in 2014. There ...
(Date:11/24/2015)... VILLAGE, Nev. , Nov. 24, 2015  PDL BioPharma, ... John P. McLaughlin , the company,s president and chief executive ... Jaffray Healthcare Conference next week in New York ... will occur on Tuesday, December 1, 2015 at 9:30 a.m. ... Presentations." Please connect to the website at least 15 minutes ...
Breaking Biology Technology:
(Date:11/10/2015)... , Nov. 10, 2015 ... biometrics that helps to identify and verify the ... is considered as the secure and accurate method ... of a particular individual because each individual,s signature ... results especially when dynamic signature of an individual ...
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... 29, 2015  Rubicon Genomics, Inc., today announced ... of its DNA library preparation products, including the ... ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been optimized ... NGS libraries for liquid biopsies--the analysis of cell-free ... applications in cancer and other conditions. Eurofins Scientific ...
Breaking Biology News(10 mins):